Literature DB >> 22234976

Adrenocortical dysfunction in liver disease: a systematic review.

Giuseppe Fede1, Luisa Spadaro, Tania Tomaselli, Graziella Privitera, Giacomo Germani, Emmanuel Tsochatzis, Michael Thomas, Pierre-Marc Bouloux, Andrew K Burroughs, Francesco Purrello.   

Abstract

In patients with cirrhosis, adrenal insufficiency (AI) is reported during sepsis and septic shock and is associated with increased mortality. Consequently, the term "hepato-adrenal syndrome" was proposed. Some studies have shown that AI is frequent in stable cirrhosis as well as in cirrhosis associated with decompensation other than sepsis, such as bleeding and ascites. Moreover, other studies showed a high prevalence in liver transplant recipients immediately after, or some time after, liver transplantation. The effect of corticosteroid therapy in critically ill patients with liver disease has been evaluated in some studies, but the results remain controversial. The 250-μg adreno-cortico-tropic-hormone stimulation test to diagnose AI in critically ill adult patients is recommended by an international task force. However, in liver disease, there is no consensus on the appropriate tests and normal values to assess adrenal function; thus, standardization of normal ranges and methodology is needed. Serum total cortisol assays overestimate AI in patients with cirrhosis, so that direct free cortisol measurement or its surrogates may be useful measurements to define AI, but further studies are needed to clarify this. In addition, the mechanisms by which liver disease leads to adrenal dysfunction are not sufficiently documented. This review evaluates published data regarding adrenal function in patients with liver disease, with a particular focus on the potential limitations of these studies as well as suggestions for future studies.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22234976     DOI: 10.1002/hep.25573

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  35 in total

Review 1.  Osteoporosis across chronic liver disease.

Authors:  M Guarino; I Loperto; S Camera; V Cossiga; C Di Somma; A Colao; N Caporaso; F Morisco
Journal:  Osteoporos Int       Date:  2016-02-04       Impact factor: 4.507

Review 2.  Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.

Authors:  Gaetano Bertino; Graziella Privitera; Francesco Purrello; Shirin Demma; Emanuele Crisafulli; Luisa Spadaro; Nikolaos Koukias; Emmanuel A Tsochatzis
Journal:  Intern Emerg Med       Date:  2016-06-07       Impact factor: 3.397

3.  Clinical factors associated with biochemical adrenal-cortisol insufficiency in hospitalized patients.

Authors:  Stephanie M Gwin; Annika K Khine; Anat Ben-Shlomo; James Mirocha; Ning-Ai Liu; Renee C Sheinin; Shlomo Melmed
Journal:  Am J Med       Date:  2014-03-13       Impact factor: 4.965

4.  Opposing effects of prednisolone treatment on T/NKT cell- and hepatotoxin-mediated hepatitis in mice.

Authors:  Hyo-Jung Kwon; Young-Suk Won; Ogyi Park; Dechun Feng; Bin Gao
Journal:  Hepatology       Date:  2014-01-21       Impact factor: 17.425

Review 5.  Immunologic, hemodynamic, and adrenal incompetence in cirrhosis: impact on renal dysfunction.

Authors:  Louise Madeleine Risør; Flemming Bendtsen; Søren Møller
Journal:  Hepatol Int       Date:  2014-09-27       Impact factor: 6.047

6.  Free Cortisol Is a More Accurate Marker for Adrenal Function and Does Not Correlate with Renal Function in Cirrhosis.

Authors:  Eleni Theocharidou; Olga Giouleme; Sotirios Anastasiadis; Aikaterini Markopoulou; Efstathios Pagourelias; Themistoklis Vassiliadis; Athanasios Fotoglidis; Polyxeni Agorastou; Aristeidis Slavakis; Aikaterini Balaska; Maria G Kouskoura; Thomas D Gossios; Asterios Karagiannis; Christos S Mantzoros
Journal:  Dig Dis Sci       Date:  2019-01-19       Impact factor: 3.199

Review 7.  Regulation of cortisol bioavailability--effects on hormone measurement and action.

Authors:  Ilias Perogamvros; David W Ray; Peter J Trainer
Journal:  Nat Rev Endocrinol       Date:  2012-08-14       Impact factor: 43.330

Review 8.  Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.

Authors:  Juan Carlos Q Velez; George Therapondos; Luis A Juncos
Journal:  Nat Rev Nephrol       Date:  2019-11-13       Impact factor: 28.314

Review 9.  Update on adrenal insufficiency in patients with liver cirrhosis.

Authors:  Anca Trifan; Stefan Chiriac; Carol Stanciu
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

Review 10.  Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management.

Authors:  Sara Blasco-Algora; José Masegosa-Ataz; María Luisa Gutiérrez-García; Sonia Alonso-López; Conrado M Fernández-Rodríguez
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.